Although PARP1 inhibitor therapy has predominantly targeted Breast Cancer (BRCA)-mutated cancers, there is growing evidence that PARP1 inhibitor treatment for non-BRCA-mutant tumors might be beneficial for CIN+ tumors [16,17]. This evidence concerns the gene PARP1 and cancer.